Results from the Phase III REDEFINE 1 trial show that CagriSema led to a 22.7% mean weight reduction at 68 weeks in adults ...

According to Sun Life, cancer is the most common and costly condition that its members face. Second opinions are important ...

The Acuvue Oasys Max 1-Day Multifocal marks the first and only daily disposable contact lens to be available for people with ...

Immuno Cure BioTech and PharmaJet are working together on a clinical study to test the effectiveness of PharmaJet’s ...

Cancer patients’ journeys are complex and the benefit of a drug goes well beyond survival, even in cases of incurable and/or ...

Leading stakeholders in the industry react to how evolving US policies, payer demands, and vertical integration are reshaping ...

Pedro Valencia, VP, asset strategy leadership, oncology, outlines how unmet need, treatment stagnation, and pipeline innovation shape the company’s approach to solid tumor oncology following key data ...